At #ESMO26: In an analysis of the phase 3 RELATIVITY-047 trial comparing relatlimab + nivolumab vs nivolumab alone in patients with melanoma, high baseline levels of LAG3hi CD8+ T cells were associated with improved response in the combination arm dlvr.​it/TW34gN